Zobrazeno 1 - 10
of 88
pro vyhledávání: '"Robert, Biesen"'
Autor:
Denis Poddubnyy, Torsten Diekhoff, Sevtap Tugce Ulas, Robert Biesen, Hildrun Haibel, Iris Eshed, Fabian Proft, Mikhail Protopopov, Valeria Rios Rodriguez, Judith Rademacher, Juliane Greese, Dominik Deppe, Felix Radny, Katharina Ziegeler, Kay Geert A Hermann, Carsten Stelbrink
Publikováno v:
RMD Open, Vol 10, Iss 1 (2024)
Objective Reliable interpretation of imaging findings is essential for the diagnosis of axial spondyloarthritis (axSpA) and requires a high level of experience. We investigated experience-dependent differences in diagnostic accuracies using X-ray (XR
Externí odkaz:
https://doaj.org/article/ab35a037e4a54822bdf1809e480948a1
Autor:
Mary K Crow, Lars Rönnblom, Dimitrios T Boumpas, Robert Biesen, George Bertsias, Marie-Louise Frémond, Marie Wahren-Herlenius, Giulio Cavalli, Maija-Leena Eloranta, Javier Rodríguez-Carrio, Marianne Visser, P G Conaghan, Agata Burska, Willem A Dik, Ed Vital, Jan Rehwinkel, Marjan Versnel
Publikováno v:
RMD Open, Vol 9, Iss 1 (2023)
Background Type I interferons (IFN-I) contribute to a broad range of rheumatic and musculoskeletal diseases (RMDs). Compelling evidence suggests that the measurement of IFN-I pathway activation may have clinical value. Although several IFN-I pathway
Externí odkaz:
https://doaj.org/article/5ed658da692d4ef990b67d89a35b1dad
Autor:
Mary K Crow, Lars Rönnblom, Dimitrios T Boumpas, Robert Biesen, George Bertsias, Marie-Louise Frémond, Marie Wahren-Herlenius, Giulio Cavalli, PG Conaghan, Maija-Leena Eloranta, Javier Rodríguez-Carrio, Marianne Visser, Agata Burska, Willem A Dik, Ed Vital, Jan Rehwinkel, Marjan Versnel
Publikováno v:
RMD Open, Vol 9, Iss 1 (2023)
Objectives To systematically review the literature for assay methods that aim to evaluate type I interferon (IFN-I) pathway activation and to harmonise-related terminology.Methods Three databases were searched for reports of IFN-I and rheumatic muscu
Externí odkaz:
https://doaj.org/article/acf1dfeb0fa4419ca571c1658790fe65
Autor:
Robert Biesen, Florian Kurth, Jan Zernicke, Florian Klein, Jens Klotsche, Amanthi Nadira Arumahandi de Silva, Leonie Maria Frommert, Alexander ten Hagen, Elisa Habermann, Lutz Gieselmann, Pinkus Tober-Lau, Fredrik Nils Albach, Elvin Ahmadov, Leif Erik Sander
Publikováno v:
RMD Open, Vol 8, Iss 2 (2022)
Objective The level of neutralising capacity against Omicron BA.1 and BA.2 after third COVID-19 vaccination in patients on paused or continuous methotrexate (MTX) therapy is unclear.Methods In this observational cohort study, neutralising serum activ
Externí odkaz:
https://doaj.org/article/84ca7dad6d3b427d82aed33a4720b1b0
Autor:
Lennard Ostendorf, Philipp Dittert, Robert Biesen, Ankelien Duchow, Victoria Stiglbauer, Klemens Ruprecht, Judith Bellmann-Strobl, Dominik Seelow, Werner Stenzel, Raluca A. Niesner, Anja E. Hauser, Friedemann Paul, Helena Radbruch
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
Abstract We aimed to evaluate SIGLEC1 (CD169) as a biomarker in multiple sclerosis (MS) and Neuromyelitis optica spectrum disorder (NMOSD) and to evaluate the presence of SIGLEC1+ myeloid cells in demyelinating diseases. We performed flow cytometry-b
Externí odkaz:
https://doaj.org/article/9dbd84d824d44f7f9ebb0bb35db75826
Autor:
Werner Stenzel, Udo Schneider, Robert Biesen, Gerd R Burmester, Falk Hiepe, Tilmann Kallinich, Martin Krusche, Christian Meisel, Nadine Unterwalder, Jens Klotsche, Thomas Rose, Akinori Uruha, Manuel Graf, Sae Lim von Stuckrad, Lydia Zorn-Pauly, Thomas Buttgereit
Publikováno v:
RMD Open, Vol 8, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/64c804afb42a466d90d916d7a69dde0e
Autor:
Jeffrey Siefert, Jonas Kaufmann, Felix Thiele, Thula Walter-Rittel, Julian Rogasch, Robert Biesen, Gerd R. Burmester, Holger Amthauer, Udo Schneider, Christian Furth
Publikováno v:
Diagnostics, Vol 13, Iss 1, p 157 (2023)
In this retrospective study, PET/CT data from 59 patients with suspected giant cell arteritis (GCA) were reviewed using the Deauville criteria to determine an optimal cut-off between PET positivity and negativity. Seventeen standardised vascular regi
Externí odkaz:
https://doaj.org/article/9f6939240ed24098bd9a993ff141fa16
Autor:
Jakob Höppner, Vincent Casteleyn, Robert Biesen, Thomas Rose, Wolfram Windisch, Gerd Rüdiger Burmester, Elise Siegert
Publikováno v:
Pharmaceuticals, Vol 15, Iss 10, p 1198 (2022)
Systemic Sclerosis (SSc) is a clinically heterogeneous disease that includes an upregulation of type I interferons (IFNs). The aim of this observational study was to investigate the IFN-regulated protein Sialic Acid–Binding Ig-like Lectin 1 (SIGLEC
Externí odkaz:
https://doaj.org/article/fde7c18e69ad4e4eb820302140ebe93e
Autor:
Florian Weigold, Jeannine Günther, Moritz Pfeiffenberger, Otavio Cabral-Marques, Elise Siegert, Duska Dragun, Aurélie Philippe, Ann-Katrin Regensburger, Andreas Recke, Xinhua Yu, Frank Petersen, Rusan Catar, Robert Biesen, Falk Hiepe, Gerd R. Burmester, Harald Heidecke, Gabriela Riemekasten
Publikováno v:
Arthritis Research & Therapy, Vol 20, Iss 1, Pp 1-9 (2018)
Abstract Background The chemokine receptors CXCR3 and CXCR4 are involved in the pathogenesis of fibrosis, a key feature of systemic sclerosis (SSc). It is hypothesized that immunoglobulin (Ig)G antibodies (abs) against these two receptors are present
Externí odkaz:
https://doaj.org/article/f50c80a2895a44a68faedb894ed28ddd
Autor:
Edgar Wiebe, Dörte Huscher, Désireé Schaumburg, Andriko Palmowski, Sandra Hermann, Thomas Buttgereit, Robert Biesen, Gerd-Rüdiger Burmester, Yannick Palmowski, Maarten Boers, John H Stone, Christian Dejaco, Frank Buttgereit
Publikováno v:
Annals of the Rheumatic Diseases, 81(9):heartjnl-2022-222339, 1313-1322. BMJ Publishing Group
Wiebe, E, Huscher, D R, Schaumburg, D S, Palmowski, A, Hermann, S, Buttgereit, T, Biesen, R, Burmester, G-R D, Palmowski, Y, Boers, M, Stone, J H, Dejaco, C & Buttgereit, F 2022, ' Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease ', Annals of the Rheumatic Diseases, vol. 81, no. 9, heartjnl-2022-222339, pp. 1313-1322 . https://doi.org/10.1136/annrheumdis-2022-222339
Wiebe, E, Huscher, D R, Schaumburg, D S, Palmowski, A, Hermann, S, Buttgereit, T, Biesen, R, Burmester, G-R D, Palmowski, Y, Boers, M, Stone, J H, Dejaco, C & Buttgereit, F 2022, ' Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease ', Annals of the Rheumatic Diseases, vol. 81, no. 9, heartjnl-2022-222339, pp. 1313-1322 . https://doi.org/10.1136/annrheumdis-2022-222339
ObjectivesInflammatory rheumatic and musculoskeletal diseases (iRMDs) are associated with increased systemic bone loss that is mediated by chronic inflammation, treatment with glucocorticoids (GCs) and other factors. Our objective was to analyse the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::132dd0a54c107849620dda6a548ef277
https://doi.org/10.1136/annrheumdis-2022-222339
https://doi.org/10.1136/annrheumdis-2022-222339